Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Excipients

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Excipients. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-001732-38 Sponsor Protocol Number: 1502 Start Date*: 2015-09-14
    Sponsor Name:CENTRE OSCAR LAMBRET
    Full Title: EVALUATION OF SENTINEL NODE (SN) POLICY IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE AND HIGH RISK OF RECURRENCE: RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT FRENCH INITIAL ...
    Medical condition: Intermediate-risk endometrioïd carcinomas : IAg3, IB(II)g1-2 High-risk endometrioïd carcinomas : IB-II g3 High-risk non endometrioïd carcinomas : I-II
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014827-21 Sponsor Protocol Number: RD–5103-009-08 Start Date*: 2010-09-02
    Sponsor Name:Derby Hospitals NHS Foundation Trust [...]
    1. Derby Hospitals NHS Foundation Trust
    2. Derby Hospitals NHS Foundations Trust
    Full Title: A single centre double blind randomised controlled trial investigating the use of dexamethasone in the treatment of acute tonsillitis.
    Medical condition: Acute bacterial tonsillitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003557-15 Sponsor Protocol Number: HMB-ICU Start Date*: 2018-08-31
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: A Study to Investigate the Effect of β-Hydroxy-β-Methylbutyrate (HMB) on Skeletal Muscle Wasting in Early Critical Illness.
    Medical condition: Critical illness
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10077264 Critical illness PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-005242-36 Sponsor Protocol Number: K40-3 Start Date*: 2006-12-13
    Sponsor Name:Moberg Derma AB
    Full Title: A multicenter, randomised, double-blind, placebo-controlled clinical study evaluating efficacy, safety and tolerability of topical K40 in 8 weeks treatment of adult patients with moderate to severe...
    Medical condition: Seborrhoeic Dermatitis of the scalp.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039794 Seborrhoeic dermatitis capitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015619-42 Sponsor Protocol Number: XPF-001-202 Start Date*: 2010-02-09
    Sponsor Name:Xenon Pharmaceuticals Inc.
    Full Title: Phase 2a, Single-Blind, Placebo-Controlled, 3-Period, 2-Treatment, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients with Inherited...
    Medical condition: Inherited erythromelalgia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10015284 Erythromelalgia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002848-25 Sponsor Protocol Number: CN145-010 Start Date*: 2006-02-28
    Sponsor Name:Bristol-Myers Squibb SL
    Full Title: Protocol Title: A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate The Analgesic Efficacy And Safety of IV Paracetamol Versus Placebo in subjects with postope...
    Medical condition: Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001972-31 Sponsor Protocol Number: MDV3800-13 Start Date*: 2016-11-29
    Sponsor Name:Pfizer, Inc.
    Full Title: A Single Arm, Open Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001685-38 Sponsor Protocol Number: 2693-CL-0312 Start Date*: 2021-11-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (H...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) ES (Ongoing) IT (Completed) HU (Completed) FI (Completed) NL (Completed) NO (Completed) DE (Completed) PL (Completed) DK (Completed) BE (Completed) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003295-31 Sponsor Protocol Number: C3441021 Start Date*: 2019-03-15
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer
    Medical condition: Metastatic Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004314-29 Sponsor Protocol Number: CCD-06235AA1-01 Start Date*: 2015-02-27
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: MULTICENTRE, OPEN LABEL, RANDOMIZED, TWO-ARM, PARALLEL-GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF ENVARSUS® COMPARED WITH TACROLIMUS USED AS PER CURRENT CLINICAL PRACTICE IN THE INITIAL MAINTENAN...
    Medical condition: ESRD (end stage renal disease)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) ES (Completed) DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000446-34 Sponsor Protocol Number: MT-18 Start Date*: 2020-07-14
    Sponsor Name:ALK-Abelló A/S
    Full Title: A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic...
    Medical condition: Allergic rhinitis/rhinoconjunctivitis induced by house dust mite
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-000345-55 Sponsor Protocol Number: A4021016 Start Date*: 2008-06-05
    Sponsor Name:Pfizer Inc 235 East 42nd Street New York, NY 10017
    Full Title: RANDOMIZED, OPEN LABEL, PHASE III TRIAL OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN VERSUS PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Prematurely Ended) FR (Completed) ES (Completed) HU (Completed) DE (Completed) IE (Completed) CZ (Prematurely Ended) SK (Completed) IT (Prematurely Ended) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000810-44 Sponsor Protocol Number: FSJD-PMM2-2016 Start Date*: 2017-05-31
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: Phase II clinical trial to evaluate the effectiveness and safety of acetazolamide in the treatment of cerebellar syndrome in patients with PMM2-CDG deficiency.
    Medical condition: Cerebellar syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10008072 Cerebellar syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003271-35 Sponsor Protocol Number: KU-AIM-01-2018 Start Date*: 2019-01-07
    Sponsor Name:University of Copenhagen
    Full Title: STUDY OF ATTENTION AND IMPULSIVITY IN HEALTHY HUMAN VOLUNTEERS
    Medical condition: Attentional deficits and impulsive behaviour. These symptoms are common in attention deficit hyperactivity disorder, but also other conditions affecting the central nervous system such as Alzheimer...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005392-39 Sponsor Protocol Number: 213357 Start Date*: 2022-02-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL). C...
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084789 Homologous recombination deficiency positive advanced ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002932-64 Sponsor Protocol Number: APHP200133 Start Date*: 2021-07-23
    Sponsor Name:Assistance Publique - Hôpitaux de Paris (AP-HP)
    Full Title: Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD1 inhibitors
    Medical condition: melonoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003549-14 Sponsor Protocol Number: MN-166-ALS-2301 Start Date*: 2020-03-11
    Sponsor Name:MediciNova, Inc.
    Full Title: A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SU...
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002036-32 Sponsor Protocol Number: C3441006(MDV3800-06) Start Date*: 2016-12-05
    Sponsor Name:Pfizer Inc.
    Full Title: TALAPRO 1: A PHASE 2, OPEN LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE BASED CHEMOTHE...
    Medical condition: Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) ES (Ongoing) FR (Completed) BE (Completed) GB (Completed) AT (Completed) DK (Prematurely Ended) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002653-35 Sponsor Protocol Number: R668-AD-1424 Start Date*: 2016-01-14
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolera...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) BE (Completed) GB (Completed) NL (Completed) SK (Completed) AT (Completed) IE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001754-18 Sponsor Protocol Number: CLR_15_03 Start Date*: 2017-06-07
    Sponsor Name:Sun Pharma Advanced Research Company Ltd.
    Full Title: A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myel...
    Medical condition: Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    19.1 100000004864 10009015 Chronic myeloid leukemia LLT
    19.1 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Prematurely Ended) ES (Ongoing) HU (Completed) RO (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 10:48:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA